News for Regeneron Pharmaceuticals Stock (REGN)

Regeneron (REGN) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research • 10/24/24

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

GlobeNewsWire • 10/24/24

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI

GlobeNewsWire • 10/24/24

Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case

Reuters • 10/22/24

5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

Zacks Investment Research • 10/22/24

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

GlobeNewsWire • 10/18/24

These 3 Stocks Are Screaming Oversold: Seize the Opportunity

Benzinga • 10/11/24

Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research • 10/10/24

Regeneron Gains 13.5% Year to date: How to Play the Stock?

Zacks Investment Research • 10/08/24

Concerns Over Muscle Loss with GLP-1 Weight Loss Drugs (LLY, NVO, REGN)

GuruFocus • 10/07/24

Should You Buy the Dip on This Top Growth Stock?

The Motley Fool • 10/05/24

Stock Picks From Seeking Alpha's September 2024 New Analysts

Seeking Alpha • 10/04/24

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Zacks Investment Research • 09/30/24

Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD

Investopedia • 09/27/24

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

Benzinga • 09/27/24

Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD

WSJ • 09/27/24

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'

Reuters • 09/27/24

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

Investors Business Daily • 09/27/24

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

GlobeNewsWire • 09/27/24

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

GlobeNewsWire • 09/27/24

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

GlobeNewsWire • 09/27/24

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

GlobeNewsWire • 09/27/24

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

GlobeNewsWire • 09/26/24

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Seeking Alpha • 09/25/24

Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?

Benzinga • 09/24/24